

CAPKR publications: February 2022 – February 2024

1. Bego, M., N. Oatel, R. Cristofolletti, A. Rostami-Hodjegan. (2022) Proof of Concept in Assignment of Within-Subject Variability during Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology using Physiologically Based Pharmacokinetic Modeling, *AAPS Journal*. 5;24(1):21
2. Galetin A, Zhang L, Rodrigues AD, Huang SM (2022) Drug-drug interactions. In Atkinson's Principles of Clinical Pharmacology (Huang SM, Lertora JLL, Vicini P, Atkinson AJ Jr eds), 4th edition, Elsevier, 241–265. doi:10.1016/B978-0-12-819869-8.00013-6
3. Murata Y, Neuhoff S, Rostami-Hodjegan A, Takita H, Al-Majdoub ZM, Ogungbenro K. (2022) In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition. *AAPS J*. 2022 Jan 13;24(1):28. doi: 10.1208/s12248-021-00675-w.
4. Scotcher D, Galetin A (2021) PBPK Simulation-Based Evaluation of Ganciclovir Crystalluria Risk Factors: Effect of Renal Impairment, Old Age, and Low Fluid Intake. *AAPS J*. 24(1):13. doi: 10.1208/s12248-021-00654-1.
5. Vasilogianni A-M, Al-Majdoub ZM, Achour B, Peters SA, Rostami-Hodjegan A, and Barber J (2021) Proteomics of Colorectal Cancer Liver Metastasis: a Quantitative Focus on Drug Elimination and Pharmacodynamics Effects. *Br J Clin Pharmacol*, doi: 10.1111/bcp.15098.
6. Willemin, ME. Van Der Made, TK, Pijpersm, I., Dillen, L., Kunze, A., Jonkers, S., Steemans, K., Tutelaars, A., Jacobs, F., Monshouwer, M., Scotcher, D., Rostami-Hodjegan, A., Galetin, A., Snoeys, J. (2021) Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug-Drug Interactions. *Clin Pharmacokinet*. 2021 Sep;60(9):1187-1199.

7. Achour B, Gosselin P, Terrier J, Gloor Y, Al-Majdoub ZM, Polasek TM, Daali Y, Rostami-Hodjegan A, Reny JL (2022). Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities. *Clin Pharmacol Ther.* 111(6):1268-1277. doi: 10.1002/cpt.2576.
8. Barber J, Al-Majdoub ZM, Couto N, Vasilogianni A-M, Tillmann A, Alrubia S, Rostami-Hodjegan A and Achour B (2022). Label-Free but Still Constrained: Assessment of Global Proteomic Strategies for the Quantification of Hepatic Enzymes and Transporters. *Drug Metab and Dispos.* doi.org/10.1124/dmd.121.000780.
9. Chu X, Prasad B, Neuhoff S, Yoshida K, Leeder JS, Mukherjee D, Taskar K, Varma MV, Zhang X, Yang X, Galetin A (2022) Clinical implications of altered drug transporter abundance/function and PBPK modeling in specific populations: An ITC perspective. *Clin Pharmacol Ther.* doi: 10.1002/cpt.2643.
10. Daali Y, Rostami-Hodjegan A, Samer CF (2022). Editorial: Precision Medicine: Impact of Cytochromes P450 and Transporters Genetic Polymorphisms, Drug-Drug Interactions, Disease on Safety and Efficacy of Drugs. *Front Pharmacol.* 18;12:834717. doi: 10.3389/fphar.2021.834717.
11. Docci L, Milani N, Ramp T, Romeo AA, Godoy P, Franyuti DO, Krähenbühl S, Gertz M, Galetin A, Parrott N, Fowler S (2022). Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies. *Lab Chip.* 22(6):1187-1205. doi: 10.1039/d1lc01161h.
12. Frechen S, Rostami-Hodjegan A (2022). Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom? *Pharm Res.* doi: 10.1007/s11095-022-03250-w.

13. Murata Y, Neuhoff S, Rostami-Hodjegan A, Takita H, Al-Majdoub ZM, Ogungbenro K (2022). In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition. *AAPS J.* 13;24(1):28. doi: 10.1208/s12248-021-00675-w.

14. Tan SPF, Scotcher D, Rostami-Hodjegan A, Galetin A (2022). Effect of chronic kidney disease on the renal secretion via organic anion transporters (OAT)1/3: Implications for PBPK modelling and dose adjustment *Clin Pharmacol Ther.* doi:10.1002/cpt.2642

15. Vasilogianni A-M, Al-Majdoub ZM, Achour B, Peters SA, Barber J and Rostami-Hodjegan A (2022). Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients with Colorectal Cancer Metastasis. *Clin Pharmacol Ther.* doi:10.1002/cpt.2633.

16. Vasilogianni A-M, El-Khateeb E, Achour B, Alrubia S, Rostami-Hodjegan A, Barber J and Al-Majdoub ZM (2022). A Family of QconCATs (Quantification conCATemers) for the Quantification of Human Pharmacological Target Proteins. *J Proteom.* 15;261:104572. doi.org/10.1016/j.jprot.2022.104572.

17. Vasilogianni, A-M, El-Khateeb, E, Al-Majdoub, ZM, Alrubia, S, Rostami-Hodjegan, A, Barber J and Achour B (2022). Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease. *J Proteom.* doi.org/10.1016/j.jprot.2022.104601.

18. Ahmed AN, Rostami-Hodjegan A, Barber J, Al-Majdoub ZM (2022). Examining Physiologically-Based Pharmacokinetic (PBPK) Model Assumptions for Cross-Tissue Similarity of kcat: The Case Example of Uridine 5'-diphosphate Glucuronosyltransferase (UGT). *Drug Metab Dispos.* DOI: 10.1124/dmd.121.000813

19. Alrubia S, Mao J, Chen Y, Barber J, Rostami-Hodjegan A (2022). Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs. *Clinical Pharmacokinetics*. doi: 10.1007/s40262-022-01169-4

20. Alrubia S, Al-Majdoub ZM, Achour B, Rostami-Hodjegan A, Barber J (2022). Quantitative Assessment of the Impact of Crohn's Disease on Protein Abundance of Human Intestinal Drug-Metabolising Enzymes and Transporters. *J Pharma Sci*. doi: 10.1016/j.xphs.2022.07.012

21. Milani N, Parrott N, Ortiz Franyuti D, Godoy P, Galetin A, Gertz M, Fowler S (2022). Application of a gut-liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil. *Lab Chip*. 22(15):2853-2868. doi: 10.1039/d2lc00276k

22. Takita H, Scotcher D, Chu X, Yee KL, Ogungbenro K, Galetin A (2022). Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease. *Clin Pharmacol Ther*. 112(3):615-626. doi: 10.1002/cpt.2672.

23. Achour B, Rostami-Hodjegan A (2022). Liquid Biopsy Only Restricted to Diagnostics or Can it Go Beyond the Confines of Genotyping and Phenotyping for Quantitative Pharmacology? *Clin Pharmacol Ther*. 112(6):1152-1153. doi: 10.1002/cpt.2732.

24. Rajput AJ, Aldibani HKA, Rostami-Hodjegan, A (2023). In-Depth Analysis of Patterns in Selection of Different Physiologically-Based Pharmacokinetic Modeling Tools: Part I - Applications and Rationale Behind the Use of Open Source-Code Software. *Biopharmaceutics & Drug Disposition*. doi: 10.1002/bdd.2357

25. Cleary Y, Kletzl H, Grimsey P, Heinig K, Ogungbenro K, Baumann HES, Frey N, Aarons L, Galetin A, Gertz M (2023). Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdipam and Its Impact on Drug-Drug Interactions in Children. *Clin Pharmacokinet*. doi: 10.1007/s40262-023-01241-7.

26. Barber J, Al-Majdoub ZM, Couto N, Howard M, Elmorsi Y, Scotcher D, Alizai N, de Wildt S, Stader F, Sepp A, Rostami-Hodjegan A, Achour B (2023). Toward Systems-Informed Models for Biologics Disposition: Covariates of the Abundance of the Neonatal Fc Receptor (FcRn) in Human Tissues and Implications for Pharmacokinetic Modelling. *Eur J Pharm Sci*. doi: 10.1016/j.ejps.2023.106375.

27. Mostafa S, Polasek TM, Bousman C, Rostami-Hodjegan A, Sheffield LJ, Everall I, Pantelis C, Kirkpatrick CMJ (2022) Delineating gene-environment effects using virtual twins of patients treated with clozapine. *CPT Pharmacometrics Syst Pharmacol*. 2022 doi: 10.1002/psp4.12886.

28. Vasilogianni AM, Al-Majdoub ZM, Achour BA, Peters SA, Rostami-Hodjegan A, Barber J (2023). Proteomic Quantification of Receptor Tyrosine Kinases Involved in the Development and Progression of Colorectal Cancer Liver Metastasis. *Front Oncol*. DOI: 10.3389/fonc.2023.1010563

29. Hermann R, Rostami-Hodjegan A, Zhao P, Ragueneau-Majlessi I (2023). Seeing What Is Behind the Smokescreen: A Systematic Review of Methodological Aspects of Smoking Interaction Studies over the Last Three Decades and Implications for Future Clinical Trials. *Clinical and Translational Science*. DOI: 10.1111/cts.13494

30. Yau E, Gertz M, Ogungbenro K, Aarons L, Olivares-Morales (2023). A "middle-out approach" for the prediction of human drug disposition from preclinical data using

- simplified physiologically based pharmacokinetic (PBPK) models. *CPT Pharmacometrics Syst Pharmacol*. DOI: 10.1002/psp4.12915.
31. Aldibani HKA, Rajput AJ, Rostami-Hodjegan, A (2023). In-Depth Analysis of Patterns in Selection of Different Physiologically-Based Pharmacokinetic Modeling Tools: Part II - Assessment of Model Reusability and Comparison Between Open and Non-Open Source-Code Software. *Biopharmaceutics & Drug Disposition*. doi: 10.1002/bdd.2360.
 32. Church S, Hyrich KL, Ogungbenro K, Unwin RD, Barton A, Bluett J (2023). Development of a sensitive biochemical assay for the detection of tofacitinib adherence. *Anal Methods*; 15(14):1797-1801. doi: 10.1039/d2ay01800d.
 33. Melillo N, Scotcher D, Kenna JG, Green C, Hines CDG, Laitinen I, Hockings PD, Ogungbenro K, Gunwhy ER, Sourbron S, Waterton JC, Schuetz G, Galetin A (2023). Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug-Drug Interactions in Rats. *Pharmaceutics* 15(3):896. doi: 10.3390/pharmaceutics15030896.
 34. Yau E, Olivares-Morales A, Ogungbenro K, Aarons L, Gertz M (2023). Investigation of simplified physiologically-based pharmacokinetic models in rat and human. *CPT Pharmacometrics Syst Pharmacol*;12(3):333-345. doi: 10.1002/psp4.12911.
 35. Cleary Y, Kletzl H, Grimsey P, Heinig K, Ogungbenro K, Baumann HES, Frey N, Aarons L, Galetin A, Gertz M (2023). Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children. *Clin Pharmacokinet*. doi: 10.1007/s40262-023-01241-7.
 36. Cristofolletti R, Rostami-Hodjegan A. (2023) Linking in vitro-in vivo extrapolations with physiologically based modeling to inform drug and formulation development. *Biopharm*

Drug Dispos. 44(4):289-291.

doi: 10.1002/bdd.2375.

37. El-Khateeb E, Chinnadurai R, Al Qassabi J, Scotcher D, Darwich AS, Kalra PA, Rostami-Hodjegan A. (2023) Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease. *Ther Drug Monit.*
doi: 10.1097/FTD.0000000000001108.
38. Han C, Sun T, Chirumamilla SK, Bois FY, Xu M, Rostami-Hodjegan A. (2023) Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn's Disease Patients through PBPK Modeling. *Pharmaceutics.* doi: 10.3390/pharmaceutics15092237.
39. Hermann R, Rostami-Hodjegan A, Zhao P, Ragueneau-Majlessi I. (2023) Seeing what is behind the smokescreen: A systematic review of methodological aspects of smoking interaction studies over the last three decades and implications for future clinical trials. *Clin Transl Sci.* 16(5):742-758. doi: 10.1111/cts.13494.
40. Izat N, Bolleddula J, Abbasi A, Cheruzel L, Jones RS, Moss D, Ortega-Muro F, Parmentier Y, Peterkin VC, Tian D-D, Venkatakrisnan K, Zientek MA, Barber J, Houston JB, Galetin A, and Scotcher D (2023) Challenges and opportunities for in vitro-in vivo extrapolation of aldehyde oxidase-mediated clearance: Towards a roadmap for quantitative translation. *Drug Metab Dispos.* <https://doi.org/10.1124/dmd.123.001436>
41. Tan PFS, Willemin ME, Snoeys J, Shen H, Rostami-Hodjegan A, Scotcher D, Galetin A. (2023) Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease. *Clin Pharmacol Ther.* doi: 10.1002/cpt.3029

42. Mostafa S, Rafizadeh R, Polasek TM, Bousman CA, Rostami-Hodjegan A, Stowe R, Carrion P, Sheffield LJ, Kirkpatrick CMJ. Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia. *CPT Pharmacometrics Syst Pharmacol*. 2024. doi: 10.1002/psp4.13093

43. Tsakalozou E, Fang L, Bi Y, van den Heuvel M, Ahmed T, Tsang YC, Lionberger R, Rostami-Hodjegan A, Zhao L. Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products-a Meeting Report. *AAPS J*. 2024. 10;26(1):14. doi: 10.1208/s12248-023-00884-5

44. Han C, Sun T, Chirumamilla SK, Bois FY, Xu M, Rostami-Hodjegan A. Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn's Disease Patients through PBPK Modeling. *Pharmaceutics*. 2023. 15(9):2237. doi: 10.3390/pharmaceutics15092237

45. Vasiogianni, AM, Alrubia S., El-Khateeb, E., Al-Majdoub, SM., Couto, N., Achour, B., Rostami-Hodjegan, A., Barber, J., Complimentarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transfers in the human liver, *Mol Omics* 2023. doi: 0.1039/D3MO00144J

46. Tan, SPF., Willemin, ME., Snoeys, J., Shen, H., Rostami-Hodjegan, A., Scotcher, D., Galetin, A., Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease, *Clin Pharmacol Ther* 2023 Dec 114(6):1243-1253. doi:10.1002/cpt.3029

47. Hodson D, Mistry H, Guzzetti S, Davies M, Staniszewska A, Farrington P, Cadogan E, Yates J, Aarons L, Ogungbenro K. Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway. *CPT Pharmacometrics Syst Pharmacol*. 2023 Nov;12(11):1640-1652. doi: 10.1002/psp4.13026.

48. Francis L, Ogungbenro K, De Bruyn T, Houston JB, Hallifax D. Exploring the boundaries for in vitro-in vivo extrapolation: use of isolated rat hepatocytes in co-culture and impact of albumin binding properties in the prediction of clearance of various drug types. *Drug Metab Dispos.* 2023 Nov;51(11):1463-1473. doi: 10.1124/dmd.123.001309.
49. Hodson D, Mistry H, Yates J, Farrington P, Staniszewska A, Guzzetti S, Davies M, Aarons L, Ogungbenro K. Radiation in combination with immune checkpoint blockade and DNA damage response inhibitors in mice: dosage optimization in MC38 syngeneic tumors via modelling and simulation. *J Pharmacol Exp Ther.* 2023 Oct;387(1):44-54. doi: 10.1124/jpet.122.001572.
50. Nørgaard RA, Bhatt DK, Järvinen E, Stage TB, Gabel-Jensen C, Galetin A, Säll C (2023) Evaluating drug-drug interaction risk associated with peptide analogues using advanced in vitro systems. *Drug Metab Dispos.* doi: 10.1124/dmd.123.001441.
51. Galetin A, Brouwer KLR, Tweedie D, Yoshida K, Sjöstedt N, Aleksunes L, Chu X, Evers R, Hafey MJ, Lai Y, Matsson P, Riselli A, Shen H, Sparreboom A, Varma MVS, Yang J, Yang X, Yee SW, Zamek-Gliszczyński MJ, Zhang L, Giacomini KM. (2024) Membrane transporters in drug development and as determinants of precision medicine. *Nat Rev Drug Discov.* doi: 10.1038/s41573-023-00877-1